MAGELLAN LONGEVITY
HomeResearchStudy library › Efficacy and safety of retinaldehyde 0.1% and 0.05% creams used to…
Study summary · Skin, hair & photoaging

What are the efficacy and safety of new anti-aging creams containing retinaldehyde (RAL) at 0.1% and 0.05% for treating photoaged skin?

In one paragraph

Retinaldehyde Night Serum, a randomized trial — after 3 months, both RAL 0.1% and RAL 0.05% groups showed 95% overall improvement in photoaging. Scope: over 3 months, and the abstract states no limitations. Source: J Cosmet Dermatol 2018, PMID 29663701.

Source: J Cosmet Dermatol 2018, PMID 29663701 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

J Cosmet Dermatol · 2018 · PMID 29663701 · DOI 10.1111/jocd.12551

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Retinaldehyde creams at 0.1% and 0.05% improve skin hydration and texture, but only the 0.1% concentration also improves the melanin index.

The question

What are the efficacy and safety of new anti-aging creams containing retinaldehyde (RAL) at 0.1% and 0.05% for treating photoaged skin?

What they tested

Retinaldehyde (RAL) creams at 0.1% and 0.05% will be effective and safe in treating photoaged skin, similar to retinoic acid but with a better safety profile.

How they did it

Forty female Korean volunteers applied either RAL 0.1% or RAL 0.05% creams twice daily for 3 months. Quantitative assessments of wrinkles and skin texture on crow's feet were performed using the Antera 3D system. Transepidermal water loss (TEWL), skin hydration, melanin index, and skin brightness were also evaluated. Overall improvement was assessed by patients and dermatologists using a five-point scale.

What they found

After 3 months, both RAL 0.1% and RAL 0.05% groups showed 95% overall improvement in photoaging. Both concentrations significantly improved skin texture (13.7% for RAL 0.1%, 12.6% for RAL 0.05%), reduced TEWL (14.5% for RAL 0.1%, 17.9% for RAL 0.05%), and increased hydration (10.2% for RAL 0.1%, 6.0% for RAL 0.05%). No statistical differences were observed between the two groups for these parameters. Only RAL 0.1% significantly improved the melanin index by 6.5%. Both creams were well tolerated.

Improvements in Skin Parameters After 3 Months of Retinaldehyde Cream Application
Values shown: Percentage Change (%)
RAL 0.1% Overall Improvement95
RAL 0.05% Overall Improvement95
RAL 0.1% Textural Improvement13.7
RAL 0.05% Textural Improvement12.6
RAL 0.1% TEWL Reduction14.5
RAL 0.05% TEWL Reduction17.9
RAL 0.1% Hydration Increase10.2
RAL 0.05% Hydration Increase6
RAL 0.1% Melanin Index Improvement6.5
RAL 0.05% Melanin Index Improvement0

Both RAL 0.1% and 0.05% creams showed 95% overall improvement. RAL 0.1% led to a 13.7% textural improvement, 14.5% TEWL reduction, 10.2% hydration increase, and 6.5% melanin index improvement. RAL 0.05% led to a 12.6% textural improvement, 17.9% TEWL reduction, and 6.0% hydration increase, with no significant melanin index improvement.

What it means

Both RAL 0.1% and RAL 0.05% creams are well tolerated and improve skin hydration and texture. However, only the RAL 0.1% cream significantly improved the melanin index.

Limitations

The study was conducted on a specific population (40 female Korean volunteers), which may limit generalizability. The abstract does not mention a placebo control group, which could affect the interpretation of the results.

“both retinaldehyde creams afforded significant textural improvements, reduced water loss, increased hydration”— from the published abstract, J Cosmet Dermatol 2018

The paper at a glance

TitleEfficacy and safety of retinaldehyde 0.1% and 0.05% creams used to treat photoaged skin: a randomized double-blind controlled trial
JournalJ Cosmet Dermatol
Year2018
PMID29663701 ↗
DOI10.1111/jocd.12551 ↗
TopicSkin, hair & photoaging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Retinaldehyde Night Serum

Randomized controlled trials of topical retinaldehyde report improvements in fine lines, skin texture and hydration and other signs of photoaging, with tolerability better than prescription retinoic acid;

Retinaldehyde Night Serum

Retinaldehyde (also called retinal or RAL) is a naturally occurring metabolite of vitamin A and the…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). What are the efficacy and safety of new anti-aging creams containing retinaldehyde (RAL) at 0.1% and 0.05% for treating photoaged skin? [Plain-English summary of J Cosmet Dermatol 2018, PMID 29663701, DOI 10.1111/jocd.12551]. Magellan Longevity. https://magellanlongevity.com/study/d29663701.html
BibTeX
@misc{magellan_d29663701, title = {What are the efficacy and safety of new anti-aging creams containing retinaldehyde (RAL) at 0.1% and 0.05% for treating photoaged skin?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d29663701.html}}, note = {Plain-English summary of PubMed PMID 29663701; DOI 10.1111/jocd.12551; J Cosmet Dermatol 2018. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d29663701.html

Related studies in the Magellan library

All 32 Magellan summaries on skin, hair & photoaging →

How this summary was made. Every section above restates what the published abstract of PMID 29663701 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.